Morzsa Címlap Press Releases media Press Releases Subscribe to our press releases 2024 24/12/2024 Information relating to the financial terms of the departure of the Chairman and the Chief Executive Officer and the appointment of the new Chairman of the Board and the new Chief Executive Officer 09/12/2024 EUROAPI moves into a new chapter with new Governance and Leadership 16/10/2024 Olivier Falut appointed EUROAPI’s Chief Financial Officer 15/10/2024 EUROAPI closes the financing of its FOCUS-27 plan 10/10/2024 EUROAPI completes the financing of its FOCUS-27 plan and moves forward with its execution 05/08/2024 Availability of H1-24 Financial Report 30/07/2024 H1 2024 Results 26/06/2024 EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth 18/06/2024 EUROAPI and Priothera enter into CDMO collaboration to advance oncology project 06/06/2024 Market update - FOCUS-27 transformation project financing 06/06/2024 EUROAPI reaches major Health IPCEI milestone with official notification from European Commission 23/05/2024 EUROAPI strengthens its presence in animal health with a €130-150 million supply contract 22/05/2024 Combined General Meeting of May 22, 2024 13/05/2024 Evelyne Nguyen appointed EUROAPI’s Chief Financial Officer 30/04/2024 Combined General Meeting of May 22, 2024 - Availability of preparatory documents 09/04/2024 EUROAPI streamlines its Executive Committee to improve focus and efficiency 05/04/2024 05-APRIL-2024 – EUROAPI Availability of the 2023 Universal Registration Document, including the Annual Financial Report 14/03/2024 Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy 28/02/2024 Full-Year 2023 results 25/01/2024 EUROAPI enhances its CDMO capabilities through a pivotal collaboration with SpiroChem, a leading Contract Research Organization (CRO) 04/01/2024 EUROAPI strengthens its Executive Committee with the appointment of Ludwig de Mot as Executive Vice President - Chief Transformation Officer 2023 28/11/2023 EUROAPI appoints new Executive Committee members 21/11/2023 CDMO: EUROAPI completes acquisition of Biano 30/10/2023 Information relating to the financial terms of the departure of the Chief Executive Officer 25/10/2023 EUROAPI announces new governance 24/10/2023 EUROAPI increases the resources allocated to the liquidity contract with Kepler Cheuvreux 09/10/2023 Full-Year 2023 outlook revised downwards Launch of a strategic review Mid-term perspectives suspended 29/08/2023 EUROAPI to acquire BianoGMP to strengthen its CDMO expertise in the high-growth oligonucleotide market 02/08/2023 Availability of H1-23 Financial Report_02AUG23 01/08/2023 EUROAPI H1 2023 Results 13/06/2023 Health sovereignty: EUROAPI supports the supply of essential medicines to France and Europe 25/10/2023 EUROAPI announces new governance 06/06/2023 EUROAPI to invest €50 million at its Budapest site to meet the growing demand for prostaglandins 11/05/2023 Combined General Meeting of May 11, 2023 10/05/2023 EUROAPI’s Board of Directors proposes Géraldine Leveau as Director 09/05/2023 EUROAPI and Novéal sign CDMO agreement to advance cosmetic projects 26/04/2023 Availability of the Amendment n°1 of the 2022 Universal Registration Document 14/04/2023 Availability of the 2022 Universal Registration Document, including the Annual Financial Report 08/03/2023 EUROAPI Full-Year 2022 Results_March 8 2023 31/01/2023 Progressive restart of prostaglandin production at Budapest site 11/01/2023 EUROAPI’s Board of Directors proposes Mattias Perjos as independent Director 09/01/2023 Vitamin B12: EUROAPI to invest €40 million for a more efficient and sustainable production process in France 2022 07/12/2022 EUROAPI updates its 2022 financial guidance 31/10/2022 EUROAPI to reach 500 kg peptide and oligonucleotide capacity per year in Frankfurt by 2025 01/09/2022 Availability of 2022 Half-Year Financial Report 01/09/2022 EUROAPI 2022 Half-year results 22/07/2022 EUROAPI announces the success of its first global employee share plan “EUROAPI Action 2022” 21/07/2022 ESG: EUROAPI moves forward with its carbon reduction ambition and invests to build a state-of-the-art biomass boiler in France 01/07/2022 Availability of EUROAPI’s 2021 half-year results 09/06/2022 EUROAPI joins the SBF 120 and CAC Mid 60 indices 03/06/2022 EUROAPI launches its first global employee share plan “EUROAPI Action 2022” 01/06/2022 EUROAPI implements a liquidity contract with Kepler Cheuvreux 30/05/2022 CDMO: EUROAPI supports Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles 06/05/2022 EUROAPI announces the success of its listing on Euronext Paris 03/05/2022 EUROAPI announces that all conditions required for its upcoming listing on Euronext Paris have now been successfully met 01/04/2022 EUROAPI announces the French AMF approval on its prospectus and moves towards its listing on Euronext Paris expected on May 6, 2022
24/12/2024 Information relating to the financial terms of the departure of the Chairman and the Chief Executive Officer and the appointment of the new Chairman of the Board and the new Chief Executive Officer
26/06/2024 EUROAPI is moving ahead with its FOCUS-27 plan, setting the foundations for future profitable growth
06/06/2024 EUROAPI reaches major Health IPCEI milestone with official notification from European Commission
05/04/2024 05-APRIL-2024 – EUROAPI Availability of the 2023 Universal Registration Document, including the Annual Financial Report
14/03/2024 Full-year 2024 guidance suspended due to the temporary pause of API production at the Brindisi site in Italy
25/01/2024 EUROAPI enhances its CDMO capabilities through a pivotal collaboration with SpiroChem, a leading Contract Research Organization (CRO)
04/01/2024 EUROAPI strengthens its Executive Committee with the appointment of Ludwig de Mot as Executive Vice President - Chief Transformation Officer
30/10/2023 Information relating to the financial terms of the departure of the Chief Executive Officer
09/10/2023 Full-Year 2023 outlook revised downwards Launch of a strategic review Mid-term perspectives suspended
29/08/2023 EUROAPI to acquire BianoGMP to strengthen its CDMO expertise in the high-growth oligonucleotide market
13/06/2023 Health sovereignty: EUROAPI supports the supply of essential medicines to France and Europe
06/06/2023 EUROAPI to invest €50 million at its Budapest site to meet the growing demand for prostaglandins
14/04/2023 Availability of the 2022 Universal Registration Document, including the Annual Financial Report
09/01/2023 Vitamin B12: EUROAPI to invest €40 million for a more efficient and sustainable production process in France
31/10/2022 EUROAPI to reach 500 kg peptide and oligonucleotide capacity per year in Frankfurt by 2025
22/07/2022 EUROAPI announces the success of its first global employee share plan “EUROAPI Action 2022”
21/07/2022 ESG: EUROAPI moves forward with its carbon reduction ambition and invests to build a state-of-the-art biomass boiler in France
30/05/2022 CDMO: EUROAPI supports Sanofi’s mRNA vaccine platform with the development of lipid nanoparticles
03/05/2022 EUROAPI announces that all conditions required for its upcoming listing on Euronext Paris have now been successfully met
01/04/2022 EUROAPI announces the French AMF approval on its prospectus and moves towards its listing on Euronext Paris expected on May 6, 2022